## **Core Concept**
The question tests the understanding of beta-blocker pharmacology and the management of acute asthma. Propranolol is a non-selective beta-blocker that can exacerbate asthma by blocking beta-2 receptors in the lungs, which are responsible for bronchodilation. In an acute asthmatic attack, the goal is to rapidly reverse bronchoconstriction.

## **Why the Correct Answer is Right**
The correct answer, , is a short-acting beta-2 agonist (SABA) like salbutamol (albuterol). SABAs are the first-line treatment for acute asthma exacerbations because they cause bronchodilation by stimulating beta-2 receptors in the bronchial smooth muscle. This action is not significantly affected by the patient being on propranolol since the effect of propranolol on beta-2 receptors cannot be overcome by the dose of salbutamol used for acute asthma relief.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option might represent an antihistamine or another class of drug not primarily used for acute asthma relief. Antihistamines have limited role in acute asthma management.
- **Option B:** This could potentially be a muscarinic receptor antagonist like ipratropium, which can be used in asthma but is not the first choice for acute asthma attack attenuation, especially when compared to the rapid action of SABAs.
- **Option C:** This might suggest a long-acting beta agonist (LABA), which is not suitable for acute asthma relief but rather for long-term control of asthma symptoms.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that patients on beta-blockers, especially non-selective ones like propranolol, may require higher doses of beta-2 agonists like salbutamol to achieve the desired bronchodilatory effect during an acute asthma attack. However, SABAs remain the cornerstone of acute asthma management.

## **Correct Answer:** . Salbutamol (Albuterol)